MNC在中美市场打响新一轮自建产能保卫战，留给CDMO的增量订单正在减少。图源：阿斯利康 Catalent正面回应收购事件，然大客户阿斯利康已加速离开 ...

Catalent plans to invest an estimated $45 million to expand its facilities and purchase new equipment for its production ...

Catalent Pharma Solutions' latest expansion in Madison is bringing a boost to Wisconsin’s growing biohealth sector, with a ...

Catalent, which develops and manufactures drugs for pharmaceutical companies, had about $3.1 billion in sales last year. Photo: vincenzo pinto/Agence France-Presse/Getty Images ...

Catalent CEO Alessandro Maselli said on Monday he will remain at the helm of the U.S.-based contract drugmaker after it is acquired by Novo Holdings, the controlling shareholder of weight-loss ...

Catalent's deal with Elliott now makes the hedge fund an indirect player in the story of Wegovy, the first-to-market in a new class of highly effective weight-loss drugs which some analysts ...

Contract drug manufacturer Catalent Inc. is planning a major expansion of its Covid-19 vaccine production in Europe, enabling it to make more doses of Johnson & Johnson’sJNJ 0.28 % increase; ...

Catalent’s Geographic Performance. Geographically, CTLT operates via three regions — the United States, Europe and Other. Revenues from the United States were $658 million (up 2% year over ...

Catalent continues to manufacture Wegovy after all, which promises to be a highly lucrative contract going forward, given analysts believe it may drive revenues in excess of $25bn per annum.

Catalent has endured a series of operational and production-based hurdles over the last 2 periods. Read why I revised my rating on CTLT to Hold.

Catalent, Inc. and Subsidiaries. Consolidated Statements of Operations (Unaudited; dollars and shares in millions, except per share data) Three Months Ended September 30, FX Impact ...

Catalent’s net leverage ratio (see the GAAP to non-GAAP reconciliation provided later in this release) as of December 31, 2020 was 2.6x, compared to 2.6x at September 30, 2020 and 4.2x at ...